Related Experiment Video
Updated: Apr 28, 2026
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Advanced thyroid cancers: new era of treatment
Amrallah A Mohammed1, Ayman El-Shentenawy
1Oncology Center, King Abdullah Medical City-Holy Capital, Muzdallifa Streat, P.O. Box 57657, Makkah, 21995, Saudi Arabia, amrallaabdelmoneem@yahoo.com.
Abstract:
Since chemotherapy has been shown to be unsuccessful in case of advanced thyroid carcinomas, the research for new therapies is fundamental. Clinical trials of many tyrosine kinase inhibitors as well as anti-angiogenic inhibitors suggest that patients with thyroid cancer could have an advantage with new target therapy. Recently, Food and Drug Administration approved two targeted therapies, vandetanib and cabozantinib for the treatment of metastatic thyroid carcinomas with acceptable outcome. We summarized the results and the toxic effects associated with these treatments reported in clinical trials. Future trials should aim at combinations of targeted agents with or without other treatment modalities to obtain a more effective result in thyroid carcinoma treatment.
Insights
Targeted therapies like vandetanib and cabozantinib show promise for advanced thyroid cancer when chemotherapy fails. Further research into combination therapies may improve treatment outcomes for this disease.
Area of Science:
- Oncology
- Pharmacology
Background:
- Chemotherapy is often ineffective for advanced thyroid carcinomas.
- New therapeutic strategies are crucial for treating advanced thyroid cancer.
Purpose of the Study:
- To summarize the clinical trial outcomes of targeted therapies for metastatic thyroid carcinomas.
- To review the efficacy and toxic effects of vandetanib and cabozantinib.
Main Methods:
- Review of clinical trial data for targeted therapies.
- Analysis of Food and Drug Administration-approved treatments for metastatic thyroid cancer.
Main Results:
- Vandetanib and cabozantinib have demonstrated acceptable outcomes in treating metastatic thyroid carcinomas.
- Clinical trials reported specific results and toxic effects associated with these targeted therapies.
Conclusions:
- Targeted therapies, including vandetanib and cabozantinib, offer a viable treatment option for advanced thyroid cancer.
- Future research should explore combinations of targeted agents and other treatment modalities to enhance efficacy in thyroid carcinoma treatment.
More Related Videos
03:55Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
Related Concept Videos
01:27Hyperthyroidism II: Pathophysiology
01:25Hyperthyroidism I: Introduction
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...